

Rec'd PCT/PTO 12 JAN 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :
Makoto TSUNEOKA et al. : **Mail Stop: PCT**
Serial No. 10/509,073 : Attorney Docket No. 2004_1597A
Filed October 12, 2004 :
CANCER-ASSOCIATED GENE MINA 53,
PROTEIN MINA 53 AND MONOCLONAL
ANTIBODY THEREOF
[Corresponding to PCT/JP03/04699
Filed April 14, 2003]

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of the references listed on attached form PTO-1449 and any additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO-1449 is enclosed, except a copy is not provided for:

- ☐ each U.S. Patent and U.S. Patent application publication;
- ☒ each reference previously cited in the international application PCT/JP03/04699; and/or
- ☐ each reference previously cited in prior parent application Serial No. _____.

1a. ☒ This Information Disclosure Statement is submitted:

within three months of the filing date (or of entry into the National Stage) of the above-entitled application, or

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

and thus no certification and/or fee is required.

1b. ☐ This Information Disclosure Statement is submitted

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

(1) ☐ the certification of paragraph 2 below is provided, **or**

(2) ☐ the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

1c. ☐ This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

the certification of paragraph 2 below is provided, and

the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

2. It is hereby certified

- a. ☐ that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or
- b. ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.

3. ☐ Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.
4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:
- a. ☐ a full or partial English language translation submitted herewith,
 - b. ☐ a foreign patent office search report (in the English language) submitted herewith,
 - c. ☐ the concise explanation contained in the specification of the present application at page,
 - d. ☐ the concise explanation set forth in the attached English language abstract,
 - e. ☐ the concise explanation set forth below or on a separate sheet attached to the reference:
5. ☐ A foreign patent office search report citing one or more of the references is enclosed.

Respectfully submitted,

Makoto TSUNEOKA et al.

By Warren M. Cheek, Jr.
Warren M. Cheek, Jr.
Registration No. 33,367
Attorney for Applicants

WMC/dlk
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
January 12, 2005

INFORMATION DISCLOSURE STATEMENT

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

Date Submitted to PTO: January 12, 2005

ATTY DOCKET NO.
2004_1597ASERIAL NO.
10/509,073APPLICANT
Makoto TSUNEOKA et al.FILING DATE
October 12, 2004

GROUP

U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|----------------------|----|--------------------|------|------|-------|----------|-------------------------------|
| | AA | | | | | | |
| | AB | | | | | | |
| | AC | | | | | | |
| | AD | | | | | | |

FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION YES NO |
|--|----|--------------------|------|---------|-------|----------|-----------------------|
| | AE | | | | | | |
| | AF | | | | | | |

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | |
|--|----|--|
| | AG | M. Tsuneoka et al., "A Novel Myc Target Gene, Mina 53, that is Involved in Cell Proliferation", J. Biol. Chem., September 20, 2002, Vol. 277, No. 38, pp. 35450-35459. |
| | AH | A. Semov et al., "Microarray Analysis of E-Box Binding-Related Gene Expression in Young and Replicatively Senescent Human Fibroblasts", Anal. Biochem., March 1, 2002, Vol. 302, No. 1, pp. 38-51. |
| | AI | M. Tsuneoka et al., "Mina53 as a Potential Prognostic Factor for Esophageal Squamous Cell Carcinoma", Clinical Cancer Research, November 1, 2004, Vol. 10, pp. 7347-7356. |
| | AJ | K. Teye et al., "Increased Expression of a Myc Target Gene Mina53 in Human Colon Cancer", American Journal of Pathology, January 2004, Vol. 164, No. 1, pp. 205-216 |

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of form with next communication to applicant.